First-ever Phase 3 study in HPV16-positive head and neck cancer demonstrates strong enrollment progress PDS Biotech reported Q2 results alongside significant progress in its groundbreaking
Series B funding supports programmable mRNA platform with lead candidate showing promise in solid tumors Massachusetts-based Strand Therapeutics completed a $153 million Series B financing
Multi-year partnership leverages AI analytics to improve treatment outcome modeling AstraZeneca expanded its collaboration with health data firm SOPHiA GENETICS to harness AI-powered “Multimodal Analytics
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
Vepdegestrant PROTAC estrogen receptor degrader targets ER+ breast cancer with novel mechanism The FDA accepted Arvinas and Pfizer’s New Drug Application for vepdegestrant (ARV-471), granting
Melanoma vaccine combination shows numerical benefit but misses primary endpoint, shares plummet 34% IO Biotech’s Phase 3 trial evaluating its IO102/IO103 therapeutic cancer vaccine (Cylembio)
Thermo Fisher’s companion diagnostic enables precision treatment with zongertinib for rare NSCLC subset The FDA approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a
Phase 3 trial demonstrates practice-changing survival benefits in muscle-invasive disease Pfizer announced highly positive interim results from a pivotal Phase 3 trial combining its antibody-drug
HistoSonics has secured a transformative investment that values the innovative medical device company at $2.25 billion, with a consortium led by Johnson & Johnson Development
Strand Therapeutics has raised an impressive $153 million in funding to advance its pioneering programmable mRNA cancer therapy platform, with backing from pharmaceutical giants Amgen
